Zenlabs Ethica Ltd
₹
- close price
About
Incorporated in 1993, Zenlabs Ethica Ltd deals in marketing and distribution of pharmaceutical products.[1]
Key Points
- Market Cap ₹ Cr.
- Current Price ₹
- High / Low ₹ /
- Stock P/E
- Book Value ₹
- Dividend Yield %
- ROCE %
- ROE %
- Face Value ₹
Pros
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Loading peers table ...
Quarterly Results
Figures in Rs. Crores
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Raw PDF |
Profit & Loss
Figures in Rs. Crores
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Dividend Payout % |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | % |
Balance Sheet
Figures in Rs. Crores
| Equity Capital |
| Reserves |
| Total Liabilities |
| CWIP |
| Investments |
| Total Assets |
Cash Flows
Figures in Rs. Crores
| Net Cash Flow |
| Free Cash Flow |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit |
Ratios
| Debtor Days |
| Inventory Days |
| Days Payable |
| Cash Conversion Cycle |
| Working Capital Days |
| ROCE % |
Insights
In beta| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Number of permanent employees employees ・Standalone data |
|
|||||||||
| Number of therapeutic categories categories ・Standalone data |
||||||||||
| Export revenue as % of total revenue % ・Standalone data |
||||||||||
| Number of products in portfolio products ・Standalone data |
||||||||||
Requires Premium
Requires Premium
Extracted by Screener AI
Documents
Announcements
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
- Submitted Regulation 74(5) compliance certificate for quarter ended 30 September 2026.
-
Announcement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance Officer
- Nikunj Goel resigned as Company Secretary and Compliance Officer, effective close of business on 05 October 2026.
-
Announcement under Regulation 30 (LODR)-Change in Management
- Company Secretary and Compliance Officer Nikunj Goel resigned effective 05 October 2026.
- Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
-
Announcement under Regulation 30 (LODR)-Appointment of Statutory Auditor/s
- AGM on 29 Sep 2026 reappointed N. Kumar Chabbra & Co. as statutory auditors for five years.
Annual reports
-
Annual Report 2026
from bse
-
Annual Report 2025
from bse
-
Annual Report 2024
from bse
-
Annual Report 2023
from bse
-
Annual Report 2022
from bse
-
Annual Report 2021
from bse
-
Annual Report 2020
from bse
-
Annual Report 2019
from bse
-
Annual Report 2018
from bse
-
Annual Report 2017
from bse
-
Annual Report 2016
from bse
-
Annual Report 2015
from bse
-
Annual Report 2014
from bse
-
Annual Report 2013
from bse
-
Annual Report 2011
from bse
Business Overview:[1][2]
a) ZEL is a part of the Preet Remedies Group. It is a WHO–GMP certified contract manufacturing pharmaceutical firm which operates across manufacturing and distributing diversified pharmaceutical formulations under multiple divisions (Zenlabs, Coles Pharma, Mega Star), servicing both domestic and international markets including Southeast Asia.
b) The company does third party manufacturing for Preet Remedies Group which has 5 production units namely Preet Remedies Pvt. Ltd., Oasis Pharma & Phytomolecules Pvt. Ltd., Quixotic Healthcare Unit I & II, and Alpha Products. At any of these facilities, the minimum
order quantity offered is 2000 boxes
of drugs.
c) The company is also into private label manufacturing of different pharmaceutical products.